Stock Information Data is 15 minutes delayed
ContraFect Corporation — Common Stock
Nasdaq: CFRX
Price
Change
Market Cap
Volume
ContraFect Corporation — Class A Warrants
NASDAQ: CFRXW
Price
Change
52 Week Low/High
Company Overview
ContraFect Corporation is a clinical stage biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Drug resistant infections cause 2 million illnesses in the U.S. and 700,000 deaths worldwide each year. Our therapeutic product candidates from our lysin and monoclonal antibody platforms are intended to address drug-resistant infections through novel mechanisms which are highly targeted towards conserved regions of either bacteria or viruses (regions that are not prone to mutation).
Officers & Directors
Steven C. Gilman, Ph.D.
Chairman and Chief Executive Officer
Dr. Gilman most recently served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals until its acquisition by Merck & Co. Prior to joining Cubist in 2008, Dr. Gi...
View Full Profile »
Cara Cassino, M.D.
Chief Medical Officer and Executive Vice President of Research and Development
Dr. Cassino has over 20 years of experience as a clinician and executive in healthcare, including over 14 years of experience in pharmaceutical product development and over 20 successful regulatory submissions in the US and glo...
View Full Profile »
Michael Messinger, CPA
Senior Vice President, Finance
Mr. Messinger has more than 15 years of experience in finance, accounting and forecasting for clinical development. He served as Controller of Coelacanth Corporation prior to his role as Director of Finance for Lexicon Pharmace...
View Full Profile »
Nancy Dong
VP, Finance & Administration
Ms. Dong has more than 20 years of experience in accounting, strategic planning, budgeting and forecasting, organizational development, financial systems and controls. She served as controller at XL Marketing and Alley Corp pri...
View Full Profile »
Natalie Bogdanos
General Counsel and Corporate Secretary
Ms. Bogdanos has more than 18 years of in-depth legal experience, across many areas of law including contract, intellectual property, licensing, regulatory, corporate governance, securities and litigation. 12 of those years of ...
View Full Profile »
Steven C. Gilman, Ph.D.
Chairman and Chief Executive Officer
Dr. Gilman most recently served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals until its acquisition by Merck & Co. Prior to joining Cubist in 2008, Dr. Gi...
View Full Profile »
Sol Barer, Ph.D.
Lead Director
Dr. Barer joined Celanese Research Company in 1974 and formed the Biotechnology Group that was spun out to form Celgene. Dr. Barer was Chairman and Chief Executive Officer from May 1, 2006 until June 16, 2010 and served a...
View Full Profile »
Roger J. Pomerantz, M.D., F.A.C.P.
Vice Chairman
Dr. Pomerantz was formerly Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories. Previously, he served as ...
View Full Profile »
Isaac Blech
Founder and private financier of biotechnology companies
Mr. Blech's current roles include Director of ContraFect Corporation, Founder and Vice Chairman of Cerecor, Inc., a company developing new treatments for central nervous systems disorders, Vice Chairman of Edge Therapeutics, In...
View Full Profile »
Cary W. Sucoff
Owner, Equity Source Partners LLC, an advisory and consulting firm
Mr. Sucoff has served on our board of directors since May 2010. Mr. Sucoff has more than 30 years of securities industry experience encompassing supervisory, banking and sales responsibilities. He has participated in the financ...
View Full Profile »
David N. Low, Jr.
Director
Mr. Low has worked as an investment banker since 1987, with broad investment and advisory experience in the life sciences, biotechnology and medical technology sectors. Mr. Low currently serves as a Senior Advisor at Lazard Fre...
View Full Profile »
Michael J. Otto, Ph.D.
Director
Dr. Otto served as Chief Scientific Officer of Pharmasset from October 1999 until February 2012, when the company was acquired by Gilead Sciences. He led the research team responsible for the discovery of sofosbuvir for the tre...
View Full Profile »